Bevin M.B. Newman

Jones Day (Washington DC)
Lawyer (Partner)

Bevin Newman focuses on antitrust litigation, counseling, and agency practice, with an emphasis on mergers and acquisitions in highly regulated sectors, such as health care and national security. Bevin has experience in coordinating the regulatory reviews of complex and multijurisdictional transactions that involve multiple federal and state agencies. She serves as one of the Firm’s leading lawyers in Hart-Scott-Rodino premerger notification requirements and often coordinates multi-country merger reviews. Bevin also frequently represents clients in Exon-Florio reviews before the multiagency Committee on Foreign Investment in the United States (CFIUS), and she has substantial experience counseling clients in China, France, Germany, Japan, Russia, and the U.K. on federal regulation of transactions that impact U.S. national security and critical infrastructure. Bevin’s merger-related work spans diverse industries, such as retail, energy, aerospace, and defense. Bevin has a particular interest in antitrust issues in health care. She regularly advises health care clients on significant mergers, including CVS/Caremark, Caremark/AdvancePCS, the acquisitions of Great West and HealthSource by CIGNA, M-Care by Blue Cross Blue Shield of Michigan, and Clinical Laboratories by Quest Diagnostics. Bevin also has assisted in multiple health care antitrust matters for of CIGNA, Hologic, and Sutter Health. Bevin is the author of Antitrust Aspects of Mergers and Acquisitions (BNA Corp. Practice Series, 3d ed., 2006) and "An Overview of Federal Antitrust Laws and Enforcement Policies," (CCH Health Care Compliance Professionals Manual, June 2010), serves on the editorial board for the American Bar Association book, Antitrust Compliance, and is a member of the American Health Lawyers Association.

Distinctions

Linked authors

Jones Day (Houston)
Jones Day (Washington DC)
Jones Day (Washington DC)
Jones Day (Beijing)
Gibson Dunn (Hong Kong)
Jones Day (Beijing)
Winston & Strawn (New York)
Dentons (Tysons Corner)

Articles

3690 Bulletin

Bevin M.B. Newman, Geoffrey D. Oliver, Michael Sennett The Court of Appeal for the District of Columbia rejects a challenge to an FTC rule that makes the HSR Act reporting requirements cover pharmaceutical patent licenses that transfer all commercially significant rights (PhRMA)

128

The D.C. Circuit has rejected a challenge by the Pharmaceutical Research and Manufacturers of America ("PhRMA") to an FTC rule that makes the HSR Act reporting requirements cover pharmaceutical patent licenses that transfer "all commercially significant rights." The rule, adopted in 2013, (...)

Bevin M.B. Newman, Kathryn M. Fenton, Ryan C. Thomas, Tom D. Smith The U.S. DOJ prosecutes obstruction of justice by a South Korean executive in merger investigation (Hyosung Corporation)

74

A plea agreement entered into last week with the U.S. Department of Justice Antitrust Division (DOJ) provides a sobering reminder of the serious consequence of obstruction of justice, and highlights the fact that such obstruction issues can arise even in connection with seemingly routine merger (...)

Bevin M.B. Newman, Giovanna M. Cinelli, Kenneth J. Nunnenkamp, Peter J. Wang, Sébastien J. Evrard, Yizhe Zhang The Chinese MOFCOM publishes final rules on the national security review of foreign investment in national companies

64

China has published new rules to implement the national security review that will be conducted as part of the review of mergers and acquisitions by foreign investors and involving Chinese companies. These rules provide for review and potential rejection of acquisitions of Chinese companies by (...)

Bevin M.B. Newman, Giovanna M. Cinelli, H. Stephen Harris, Kenneth J. Nunnenkamp, Peter J. Wang, Sébastien J. Evrard, Yizhe Zhang The Chinese State Council publishes a notice detailing its national security review procedure for the acquisition by foreign investors of domestic companies

810

The State Council of the People’s Republic of China has published a notice detailing its national security review («NSR») procedure for the acquisition by foreign investors of domestic Chinese companies («NSR Notice»). The NSR Notice, which implements Article 31 of the PRC Anti-Monopoly Law, will be (...)

Send a message